Iovance Biotherapeutics Inc (IOVA): FY26 guidance lift improves near-term confidence, but UBS remains Neutral on Iovance

Overview

This First Read assesses Iovance's raised FY26 outlook and forthcoming oncology updates. UBS sees the guidance revision as a modestly positive sign for Amtagvi's commercial launch, while retaining a Neutral rating because the longer-term investment case depends on revenue acceleration and clinical execution.

Core views

Iovance raised FY26 revenue guidance to US$410-420m from US$350-370m. The US$415m midpoint is above UBS's US$405m estimate and consensus of US$397m. Assuming Proleukin sales of US$64m, or roughly 15% of total revenue, UBS calculates that the midpoint implies approximately 160 patients infused in 3Q26 and 168 in 4Q26—6-8 more patients than UBS and consensus had anticipated. UBS interprets the change as evidence that management has greater confidence in continued Amtagvi growth in the second half of 2026, following improved patient demand, lower patient attrition and more activated authorized treatment centers (ATCs) in 2Q26. Because management has visibility into enrollment trends and therefore 3Q, and likely 4Q, revenue, UBS considers achievement of the revised guidance likely. The report nevertheless treats the guidance increase as only incrementally positive. UBS says that while it probably supported near-term stock upside, its investment thesis still rests on revenue acceleration in 2027 and beyond. The firm seeks further clarity over the next several quarters on ATC activation, the ramp of activated centers and referral patterns, which it sees as central to judging the durability and pace of commercial growth. Clinical data are the other major potential catalysts. UBS expects updated Phase 2 Amtagvi data in second-line-or-later nonsquamous NSCLC potentially in 4Q26, although management has not guided to timing. UBS expects data from roughly 80 patients and focuses on whether the study can show a consistent objective response rate of about 25% together with a median duration of response above 12 months. It considers durability the principal differentiator, comparing this potential outcome with the roughly 3-4 month median duration of response reported for standard-of-care chemotherapy plus immunotherapy or chemotherapy alone. Consistent response rates and durable responses could support a planned 2027 supplemental biologics license application and a possible accelerated-approval route, while expanding Amtagvi's addressable market in an unmet-need indication. UBS also expects October updates in first-line melanoma for Amtagvi plus pembrolizumab and in second-line-or-later sarcoma for Amtagvi monotherapy. The firm expects the October 23 Phase 2 IOV-COM-202 melanoma update to add information on response onset, depth and durability that may read through to the ongoing global Phase 3 TILVANCE-301 trial. The October 26 sarcoma update is expected to provide longer follow-up from the first six patients, for whom prior data showed a 50% objective response rate. UBS maintains a Neutral 12-month rating and a US$7 price target, versus a US$10.99 share price on 28 September 2026. Its target is based on a 2.4x enterprise-value-to-2030 estimated peak-sales multiple, supported by discounted cash flow analysis. The report's forecasts show revenue rising from US$405m in 2026E to US$584m in 2027E, US$839m in 2028E and US$1.412bn in 2030E, with UBS EBIT moving from a US$174m loss in 2026E to US$9m profit in 2027E and US$623m in 2030E.

Analysis framework

UBS first tests the revised FY26 guidance against its own and consensus forecasts, then translates the revenue outlook into implied patient infusions after accounting for Proleukin sales. It assesses commercial momentum through demand, attrition, ATC activation and enrollment visibility, before evaluating upcoming clinical readouts through response rate and durability benchmarks. Valuation uses an EV-to-2030 estimated peak-sales multiple, cross-checked with DCF.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow support for the price target

  UBS uses DCF as supporting evidence for its price target, discounting expected future business cash flows to a present value.

• Valuation methods

  2.4x EV/2030E peak-sales multiple

  UBS values Iovance primarily by applying a 2.4x enterprise-value multiple to estimated 2030 peak sales.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Iovance Biotherapeutics Inc (IOVA.US)

  Primary covered company; commercial performance is tied to Amtagvi launch execution and pipeline clinical readouts.

  Strengths

  Raised FY26 outlook, improving demand, lower attrition and increased ATC activations support near-term launch momentum.

  Weaknesses

  The longer-term thesis still requires revenue acceleration from 2027 onward.

  Comparison

  Potential NSCLC durability of more than 12 months would compare favorably with the roughly 3-4 month median duration of response cited for standard-of-care chemotherapy plus immunotherapy or chemotherapy alone.

  Risks

  Commercial execution, pipeline trial failure, regulatory changes or delays, and greater competition in melanoma and NSCLC.

Key data

• FY26 revenue guidanceUS$410-420mRaised from US$350-370m; US$415m midpoint versus UBS US$405m and consensus US$397m.
• Implied Amtagvi patient infusions~160 in 3Q26; ~168 in 4Q26Assumes US$64m FY26 Proleukin sales; 6-8 patients above UBS and consensus.
• Potential NSCLC Phase 2 data~80 patients; ~25% ORR; >12 months median DORPotential 4Q26 update; UBS contrasts this with ~3-4 months median DOR for cited standard-of-care regimens.
• FY26E revenueUS$405mUBS forecast, rising to US$584m in 2027E and US$1.412bn in 2030E.
• Price targetUS$7.00Based on a 2.4x EV/2030E peak-sales multiple, supported by DCF.

Impact & implications

UBS views the guidance revision as improving confidence in near-term Amtagvi commercialization, but not as resolving the central question of sustained revenue acceleration after 2026. Durable clinical responses in NSCLC could broaden Amtagvi's opportunity and support the planned 2027 sBLA.

Risks

• Amtagvi commercialization in second-line-or-later melanoma may be constrained by the need to build manufacturing infrastructure, manufacturing slots and a commercial organization.
• Key pipeline programs, including Amtagvi in first-line metastatic melanoma and second-line-or-later NSCLC, could fail clinical trials.
• Changes in regulatory standards, endpoints, requirements or submission demands could delay approvals.
• Other novel therapies could intensify competition in melanoma and NSCLC.

What to watch

• Further disclosure on ATC activations, ATC ramp and referral patterns over the next several quarters.
• Potential 4Q26 Phase 2 Amtagvi data in second-line-or-later nonsquamous NSCLC, particularly response durability.
• October 23 IOV-COM-202 first-line melanoma update and October 26 sarcoma follow-up.
• The approximately November 5, 2026 3Q26 earnings report.